as of 12-05-2025 3:46pm EST
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | MADISON |
| Market Cap: | 170.1M | IPO Year: | 2007 |
| Target Price: | $4.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.91 - $2.95 | Next Earning Date: | 11-05-2025 |
| Revenue: | $450,902,000 | Revenue Growth: | 1.51% |
| Revenue Growth (this year): | 3.82% | Revenue Growth (next year): | 4.08% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Avg Cost/Share
$0.97
Shares
20,000
Total Value
$19,410.00
Owned After
20,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| La Neve Stephen R. | ARAY | CEO | Nov 19, 2025 | Buy | $0.97 | 20,000 | $19,410.00 | 20,000 |
See how ARAY stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ARAY Accuray Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.